News | Heart Failure | December 02, 2020

CMS Updates Coverage Policies for Artificial Hearts and Ventricular Assist Devices

Updated policy provides enhanced patient-centered access to artificial hearts and VADs for Medicare beneficiaries

CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.


December 2, 2020 — The Centers for Medicare and Medicaid Services (CMS) finalized updates to Medicare coverage policies for artificial hearts and ventricular assist devices (VADs) to treat patients with advanced heart failure.

While Medicare generally does not cover experimental or investigational items and services, the program has historically allowed for coverage of certain interventions when they are provided in the context of an approved clinical study or with the collection of additional clinical data. This process can allow for earlier beneficiary access to innovative treatments and technology while additional data is collected.

Prior to today, Medicare covered artificial hearts under this “coverage with evidence development” standard. The updated coverage policy CMS is announcing today will end this requirement for artificial hearts and instead allow for the more standard coverage determination process where coverage decisions are made by local Medicare Administrative Contractors (MACs).  

CMS said it believes this final decision is in the best interest of Medicare beneficiaries since careful patient selection is important, and the MACs are structured to take into account a beneficiary’s particular clinical circumstances to determine which patients will benefit from receiving an artificial heart. Although a small number of Medicare beneficiaries receive artificial hearts, the technology can save the lives of certain end-stage heart failure patients awaiting heart transplantation.     

“CMS is dedicated to improving cardiovascular health in the Medicare population,” said CMS Administrator Seema Verma. “CMS is continually updating our policies to ensure that Medicare beneficiaries have access to the latest technology and appropriate evidence-based healthcare. These coverage changes will give beneficiaries and providers more options as they choose the potentially life-saving treatments most likely to produce good health outcomes.”

The final national coverage determination, which is effective as of December 2, 2020, also provides updated coverage criteria for VADs that better aligns with current medical practice and that we believe will expand coverage to a greater number of candidates who are likely to benefit from this technology. Specifically, the updated patient criteria in the NCD aligns with the inclusion criteria derived from recent large randomized controlled trials, which demonstrated improved patient outcomes.

New CMS Coverage Policy for Ventricular Assist Devices

The decision is limited to durable, intracorporeal, left ventricular assist devices (LVADs), and does not include temporary VADs or extracorporeal membrane oxygen (ECMO). CMS is establishing coverage according to the following conditions:

   • Removes the current therapeutic intent-to-treat criteria of bridge-to-transplant (BTT) and destination therapy (DT), by removing the following BTT requirements:
   • The requirement that the patient is active on the waitlist maintained by the Organ Procurement and Transplantation Network (OPTN).
   • The requirement that the implanting site, if different than the Medicare-approved transplant center, must receive written permission from the Medicare-approved transplant center prior to implantation of the VAD.
   • Extends evidence based patient selection criteria, that previously applied only to DT,   for all LVAD procedures for short-term (e.g., bridge-to-recovery and bridge-to-transplant) or long-term (e.g., destination therapy) mechanical circulatory support (see below in covered indications). 
   • Modifies patient selection criteria to reflect the major inclusion criteria of contemporary trials.

CMS Covered Indications For LVADS

Left ventricular assist devices are covered if they are FDA-approved for short-term (e.g., bridge-to-recovery and bridge-to-transplant) or long-term (e.g., destination therapy) mechanical circulatory support for heart failure patients who meet the following criteria:

   • Have New York Heart Association (NYHA) Class IV heart failure; and
   • Have a left ventricular ejection fraction (LVEF) ≤ 25%; and
   • Are inotrope dependent - OR - have a cardiac index (CI) < 2.2 L/min/m2, while not on inotropes, and also meet one of the following:
       A. Are on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and are failing to respond; or
       B. Have advanced heart failure for at least 14 days and are dependent on an intra‐aortic balloon pump (IABP) or similar temporary mechanical circulatory support for at least 7 days.
   • Beneficiaries receiving a VAD must be managed by an explicitly identified, cohesive, multidisciplinary team of medical professionals with appropriate qualifications, training, and experience. The team embodies collaboration and dedication across medical specialties to offer optimal patient-centered care.  Collectively, the team must ensure that patients and caregivers have the knowledge and support necessary to participate in informed decision making. The team members must be based at the facility and must include individuals with experience working with patients before and after placement of a VAD.

To read the final CMS decision at: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=298&type=Closed&bc=AIgAAAAACAAA&
 

Related Content

News | Artificial Heart

April 25, 2022 – There’s no safe way to get a close-up view of the human heart as it goes about its work: you can’t just ...

Home April 25, 2022
Home
News | Artificial Heart

March 28, 2022 — Carmat, the designer and developer of the world’s most advanced total artificial heart, aiming to ...

Home March 28, 2022
Home
News | Artificial Heart

June 18, 2021 – An experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can ...

Home June 23, 2021
Home
News | Artificial Heart

February 10, 2021 - The U.S. Food and Drug Administration (FDA) has granted artificial heart developer Carmat approval ...

Home February 10, 2021
Home
News | Artificial Heart

May 27, 2020 — Carmat, a developer of the of a next generation advanced total artificial heart, announces the first ...

Home May 27, 2020
Home
News | Artificial Heart

March 10, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the SynCardia Systems 50cc temporary Total ...

Home March 10, 2020
Home
News | Artificial Heart

December 11, 2017 — CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science ...

Home December 11, 2017
Home
News | Artificial Heart

October 27, 2017 — CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its ...

Home October 27, 2017
Home
News | Artificial Heart

October 26, 2016 — The U.S. Food and Drug Administration (FDA) provided an update and additional information regarding ...

Home October 26, 2016
Home
News | Artificial Heart

August 29, 2016 — SynCardia Systems, manufacturer of the Total Artificial Heart (TAH), announced that the judge ...

Home September 13, 2016
Home
Subscribe Now